FDA approves Menveo, gives priority-review status to Gilenia

02/22/2010 | Wall Street Journal, The

Novartis received final approval from the FDA for meningococcal vaccine Menveo as well as priority-review designation for multiple sclerosis drug Gilenia. The approval for Menveo covers people ages 11 to 55, but Novartis said it also will seek approval for use of the vaccine in young children and infants.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA